Philadelphia University + Thomas Jefferson University

Rodeck, Ulrich

< Back

Profile

uxr102

Ulrich Rodeck, MD

Contact Dr. Rodeck

233 South 10th Street
Philadelphia, PA 19107

(215) 503-5622

Research and Clinical Interests

Regulation of epithelial cell fate by the epidermal growth factor receptor and associated signal transduction events; molecular mechanisms leading to adverse events of cancer therapy; adverse event reduction by developing drugs targeted to disease sites; zebrafish as an in vivo model system to investigate whole organism genotoxic stress responses.

My research interests revolve around signal transduction pathways regulating epithelial cell death and survival. Specifically, I am interested in coordinated signaling by receptor tyrosine kinases and integrins as it relates to the inappropriate survival of tumor cells. In these studies, we frequently use an EGFR antagonistic monoclonal antibody originally developed at the Wistar Institute (Rodeck et al. Cancer Res., 47:3692-6, 1987) and currently in phase II clinical trials in epithelial neoplasms (EMD59000; EMD72000). A second line of investigation focuses on molecular determinants of stress response pathways in vertebrate organisms. This work is done largely in zebrafish embryos to account or microenvironmental and tissue-specific effects. The goal of these studies is to identify targets for therapeutic intervention in cancer and inflammatory diseases.

Publications

Most Recent Peer-Reviewed Publications

  1. Tumor Metabolism in the Microenvironment of Nodal Metastasis in Oral Squamous Cell Carcinoma
  2. Distinct cell stress responses induced by ATP restriction in quiescent human fibroblasts
  3. β1 integrin- and JNK-dependent tumor growth upon hypofractionated radiation
  4. Akt kinase C-terminal modifications control activation loop dephosphorylation and enhance insulin response
  5. The triterpenoid RTA 408 is a robust mitigator of hematopoietic acute radiation syndrome in mice
  6. Radiation protection of the gastrointestinal tract and growth inhibition of prostate cancer xenografts by a single compound
  7. Immunotargeting and eradication of orthotopic melanoma using a chemokine-enhanced DNA vaccine
  8. Skinflammation and drug toxicity-A delicate balance
  9. Skin toxicity of targeted cancer agents: Mechanisms and intervention
  10. Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells
  11. Gene expression signatures modulated by epidermal growth factor receptor activation and their relationship to cetuximab resistance in head and neck squamous cell carcinoma
  12. Integration of investigative dermatology into the global biomedical research enterprise: Past, present, and future
  13. Autoregulation of kinase dephosphorylation by ATP binding to AGC protein kinases
  14. A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity
  15. Resistance of Akt kinases to dephosphorylation through ATP-dependent conformational plasticity
  16. PET imaging of EGFR expression in nude mice bearing MDA-MB-468, a human breast adenocarcinoma
  17. Differential regulation of p53 function by the N-terminal Np53 and 113p53 isoforms in zebrafish embryos
  18. A novel class of compounds with cutaneous wound healing properties
  19. Progress in epidermolysis bullosa research: Toward treatment and cure
  20. Design and development of masked therapeutic antibodies to limit off-target effects: Application to anti-EGFR antibodies